AstraZeneca may reach for Bristol's diabetes biz; Salix inks $2.6B deal for Santarus;

@FierceBiotech: Teva fills CFO position as Desheh steps up to CEO, plus more of this week's career moves in biopharma. News | Follow @FierceBiotech

@JohnCFierce: FDA bottom line: unless there's a fantastic benefit, don't approve Lemtrada. Sanofi shares slip. | Follow @JohnCFierce

@DamianFierce: Updated Ariad job-cut story: EMA committee says Iclusig OK for now; stronger label on the way. More | Follow @DamianFierce

@EmilyMFierce: ICYMI: Report proposes revamping Alzheimer's R&D. Story | Follow @EmilyMFierce

> Now that Bristol-Myers Squibb ($BMY) is getting out of early-stage diabetes work, AstraZeneca ($AZN) might move to buy up a bigger share of the pair's joint venture. Story

> Gastrointestinal drug specialist Salix Pharmaceuticals ($SLXP) is planning to pay $2.6 billion for specialty drugmaker Santarus ($SNTS). Article

> Newly public Foundation Medicine ($FMI) released its quarterly earnings, reporting that revenue for the 2013 third quarter hit $8.2 million, up substantially from $3 million in revenue during the same period a year ago. News

Medical Device News

@FierceMedDev: ICYMI: OrthoSensor links with Zimmer to sell knee replacement-balancing tech. Story | Follow @FierceMedDev

@MarkHFierce: Foundation Medicine's first quarterly earnings as a public company reflect impressive growth. Article | Follow @MarkHFierce

@MichaelGFierce: From FierceDrugDelivery this week: Novo Nordisk wins FDA approval for two automated-dose insulin pens. More | Follow @MichaelGFierce

> Chinese investors pursue groundbreaking med tech from Canada's MDI. News

> A pharma-free Covidien achieves moderate medical device growth. More

> Sequestration takes its toll on FDA user fees paid by industry. Item

Pharma News

@FiercePharma: Best-read story this morning: Top 10 Drug Patent Losses for 2014. More | Follow @FiercePharma

@CarlyHFierce:  EU watchdogs demand info on AstraZeneca's disputed Brilinta trial. More | Follow @CarlyHFierce

> Gastro specialist Salix nabs Santarus and new colitis drug in $2.6B deal. Story

> After Bristol-Myers R&D cuts, will AstraZeneca amp up its share of diabetes JV? News

> EU watchdogs demand info on AstraZeneca's disputed Brilinta trial. Article

Suggested Articles

Yale scientists have combined the gene-editing system CRISPR with gene therapy to help the immune system find tough-to-spot tumor cells.

The planned deal hit a wall when a special committee set up by Eidos turned down BridgeBio’s third and final offer.

Shares in ReNeuron fell more than one-third after the release of top-line data at the start of the month but the biotech argued the data are positive.